UNASSIGNED: The effect of chemotherapy on peritoneal @entity189 (PC) of @entity356 remains unclear. Recently, the intraperitoneal (IP) administration of @entity6023 [e.g., @entity1311 ( @entity4045 ) and @entity1205 ( @entity4420 )] during the perioperative period has shown promising results. Herein, we summarized the rationale and methodology for using IP chemotherapy with @entity6023 and reviewed the clinical results. IP administered @entity6023 remain in the IP space at an extremely high concentration for 48-72 h. The drug directly infiltrates peritoneal metastatic nodules from the surface and then produces antitumor effects, making it ideal for IP chemotherapy. There are two types of perioperative IP chemotherapy with @entity6023 : neoadjuvant intraperitoneal and systemic chemotherapy and sequential perioperative intraperitoneal chemotherapy (SPIC). In SPIC, @entity1 receive neoadjuvant IP chemotherapy and the same regimen of IP chemotherapy after @entity1104 ( @entity1104 ) until disease progression. Usually, a @entity3907 dissolved in 500-1000 mL of saline at ordinary temperature is administered through an IP access port on an outpatient basis. According to phaseIstudies, the recommended doses (RD) are as follows: IP @entity4420 , 45-60 mg/m(2); IP @entity4045 [without intravenous (IV) @entity4045 ], 80 mg/m(2); and IP @entity4045 (with IV @entity4045 ), 20 mg/m(2). Phase II studies have reported a median survival time of 14.4-24.6 mo with a 1-year overall survival of 67%-78%. A phase III study comparing S-1 in combination with IP and IV @entity4045 to S-1 with IV @entity900 started in 2011. The prognosis of @entity1 who underwent @entity1104 was better than that of those who did not; however, this was partly due to selection bias. Although several phase II studies have shown promising results, a randomized controlled study is needed to validate the effectiveness of IP chemotherapy with @entity6023 for PC of @entity356 .

Breakthrough therapy for peritoneal @entity189 of XXXX : Intraperitoneal chemotherapy with @entity6023 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity6023 :: ('MESH:D043823', 'Chemical') :: ['taxanes'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity4045 :: ('D010852', 'Chemical') :: ['PTX'] @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinomatosis'] @entity3907 :: ('MESH:C080625', 'Chemical') :: ['taxane'] @entity4420 :: ('CHEBI:16973', 'Chemical') :: ['DOC'] @entity1104 :: ('MESH:D000267', 'Disease') :: ['CRS', 'cytoreductive surgery'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel'] @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancer']
@entity356 :: (MESH:D013274,Disease) :: ['gastric cancer']
